IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11352348 B1

PDFFull Text
Date of Patent:
Jun. 07, 2022

Filed:

Nov. 30, 2020

Splicing modulator antibody-drug conjugates and methods of use

Applicant:

Eisai R&d Management Co., Ltd., Tokyo, JP;

Inventors:

Ermira Pazolli, Wayland, MA (US);

Silvia Buonamici, Boston, MA (US);

Thiwanka Samarakoon, Westwood, MA (US);

Sudeep Prajapati, Somerville, MA (US);

Nathan Fishkin, Weymouth, MA (US);

James Palacino, Wellesley, MA (US);

Michael Seiler, Belmont, MA (US);

Ping Zhu, Acton, MA (US);

Andrew Cook, Stow, MA (US);

Peter Smith, Arlington, MA (US);

Xiang Liu, Winchester, MA (US);

Shelby Ellery, Boston, MA (US);

Dominic Reynolds, Stoneham, MA (US);

Lihua Yu, Acton, MA (US);

Zhenhua Wu, Belmont, MA (US);

Shouyong Peng, Belmont, MA (US);

Nicholas Calandra, Boston, MA (US);

Megan Sheehan, Allston, MA (US);

Yonghong Xiao, Belmont, MA (US);

Assignee:

EISAI R&D MANAGEMENT CO., LTD., Tokyo, JP;

Attorney:

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Primary Examiner:

Brian J Davis

Int. Cl.
CPC ...
C07D 405/12 (2006.01); A61P 35/00 (2006.01); A61K 47/68 (2017.01); A61K 47/60 (2017.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); A61K 31/365 (2006.01); A61K 31/496 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07D 313/00 (2006.01); C07D 405/06 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07D 405/12 (2013.01); A61K 9/127 (2013.01); A61K 9/51 (2013.01); A61K 31/365 (2013.01); A61K 31/496 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61K 47/6845 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6857 (2017.08); A61K 47/6869 (2017.08); A61K 47/6871 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); C07D 313/00 (2013.01); C07D 405/06 (2013.01); C07K 16/24 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2896 (2013.01); C07K 16/3007 (2013.01); C07K 16/3092 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); G01N 2500/10 (2013.01);
Abstract

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Find Patent Forward Citations

Loading…